| Literature DB >> 30857273 |
Jarim Kim1, Yerim Kim2, Jong Seok Bae3, Ju-Hun Lee4, Hong-Ki Song5.
Abstract
To estimate the prevalence of concomitant psychiatric disorders in neurological outpatients and to assess the value of simple screening questionnaires in the identification of psychiatric symptoms, we analyzed a total of 803 patients who visited neurology clinics with neurological symptoms over a six-month period. Using self-reported questionnaires, we assessed psychiatric symptoms, such as stress (Perceived Stress Scale, PSS), depression (Patient Health Question 9, PHQ9), and anxiety (Generalized Anxiety Disorder 7, GAD7). According to the disease subtypes, we analyzed the psychiatric scales based on gender and age group. The prevalence of psychiatric comorbidities was lowest in patients with cerebrovascular disease (CVD) and highest among patients with cognitive decline and epilepsy. The overall prevalence of psychiatric symptoms markedly decreased with age. This decline was statistically significant for all questionnaires (PSS ≥ 14, p for trend = 0.027; PQH9 ≥ 10, p for trend = 0.005; GAD7 ≥ 10, p for trend = 0.002) and was more pronounced in males. Considering the high incidence of undetected psychiatric comorbidities and their associated burden, proactive psychiatric management should be included in neurological care. Psychiatric questionnaires could also be an effective screening tool for identifying psychiatric symptoms accompanying neurological symptoms.Entities:
Keywords: anxiety; cognitive dysfunction; comorbidity; depression; neurology; outpatients
Mesh:
Year: 2019 PMID: 30857273 PMCID: PMC6427503 DOI: 10.3390/ijerph16050860
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Differences in frequency and descriptive statistics across disease subtypes 1.
| Disease Subtypes | CVA | Peripheral Neuropathy ( | Headache, Pain | Dizziness | Cognitive Decline | Movement Disorder | Epilepsy | Miscellaneous | |
|---|---|---|---|---|---|---|---|---|---|
| Female | 53 (42) | 43 (52) | 129 (74) | 96 (65) | 24 (67) | 76 (58) | 37 (56) | 25 (61) | <0.001 |
| Age (mean ± SD) | 66 ± 12 | 58 ± 14 | 52 ± 14 | 55 ± 16 | 73 ± 9 | 64 ± 15 | 44 ± 17 | 54 ± 15 | <0.001 * |
| T † | a, b | b, c | c, d | c | a | b | d | c | |
| PSS ≥ 14 | 80 (64) | 63 (77) | 135 (78) | 116 (78) | 29 (81) | 96 (73) | 52 (79) | 30 (73) | 0.136 |
| PHQ9 ≥10 | 21 (17) | 19 (24) | 51 (30) | 50 (34) | 15 (44) | 31 (25) | 17 (26) | 12 (29) | 0.021 |
| GAD7 ≥10 | 14 (12) | 17 (22) | 37 (22) | 31 (22) | 7 (21) | 25 (20) | 15 (24) | 9 (23) | 0.456 |
| Insomnia | 10 (8) | 14 (17) | 41 (24) | 26 (18) | 4 (11) | 10 (8) | 8 (12) | 11 (27) | <0.001 |
| Known anxiety | 9 (7) | 17 (21) | 45 (26) | 36 (24) | 5 (14) | 18 (14) | 4 (6) | 9 (22) | <0.001 |
| Known depression | 5 (4) | 0 (0) | 11 (6) | 6 (4) | 3 (8) | 5 (4) | 4 (6) | 4 (10) | 0.125 ‡ |
| Hypertension | 73 (58) | 37 (45) | 36 (21) | 54 (36) | 18 (50) | 54 (41) | 9 (14) | 11 (27) | <0.001 |
| Diabetes | 26 (21) | 22 (27) | 14 (8) | 19 (13) | 12 (33) | 24 (18) | 6 (9) | 8 (20) | <0.001 |
| Dyslipidemia | 66 (53) | 17 (21) | 20 (11) | 21 (14) | 10 (28) | 16 (12) | 5 (8) | 10 (24) | <0.001 |
| Atrial fibrillation | 8 (6) | 0 (0) | 1 (1) | 2 (1) | 0 (0) | 2 (2) | 0 (0) | 1 (2) | 0.020 ‡ |
| Smoking | 22 (18) | 16 (20) | 23 (13) | 24 (16) | 3 (8) | 17 (13) | 12 (18) | 12 (29) | 0.187 |
| Previous stroke | 104 (83) | 1 (1) | 3 (2) | 7 (5) | 4 (11) | 10 (8) | 8 (12) | 0 (0) | <0.001 |
| Coronary artery disease | 12 (10) | 6 (7) | 5 (3) | 8 (5) | 2 (6) | 10 (8) | 0 (0) | 4 (10) | 0.042 ‡ |
| Thyroid disease | 3 (2) | 4 (5) | 3 (2) | 7 (5) | 3 (8) | 11 (8) | 4 (6) | 0 (0) | 0.058 ‡ |
1 Abbreviations: SD, standard deviation; PSS, perceived stress scale; PHQ9, patient health question 9; GAD7, generalized anxiety disorder 7; CVA, cerebrovascular attack; * Statistical significance was tested using one-way analysis of variance between groups; T, Test for post-hoc analysis; † The same letters indicate a non-significant difference between groups based on Scheffe’s multiple comparison test; ‡ Statistical significance was tested using Fisher’s exact test among groups; Percentages are presented in parentheses.
Figure 1Psychiatric symptoms according to neurological disease subtypes: (A) moderate to severe perceived stress scale (PSS ≥ 14); (B) frequency of insomnia; (C) moderate to severe depression (PHQ9 ≥ 10, blue bars) and diagnosed depression (red bars); (D) moderate to severe anxiety (GAD7 ≥ 10, blue bars) and diagnosed anxiety (red bars).
Association between age group and psychiatric illness 1.
| Age | ≤29 Years | 30–59 Years | ≥60 Years | |
|---|---|---|---|---|
| PSS ≥ 14 | 48 (88.9) | 274 (75.3) | 279 (72.5) | 0.033 |
| PHQ9 ≥ 10 | 25 (46.3) | 100 (27.9) | 91 (24.5) | 0.003 |
| Known depression | 3 (5.6) | 19 (5.2) | 16 (4.2) | 0.753 |
| GAD7 ≥ 10 | 20 (37.0) | 74 (20.9) | 61 (16.9) | 0.002 |
| Known anxiety | 6 (11.1) | 72 (19.8) | 65 (16.9) | 0.241 |
| Insomnia | 9 (16.7) | 63 (17.3) | 52 (13.5) | 0.344 |
1 Abbreviations. PSS, Perceived Stress Scale; PHQ9, Patient Health Question 9; GAD7, Generalized Anxiety Disorder 7.
Figure 2Psychiatric illness prevalence rates for the three self-reported psychiatric scales: (A) prevalence rates by age group; (B) prevalence rates by gender and age group. Note: * p < 0.05, † p < 0.01.
Association between gender and psychiatric illness1.
| Gender | Females | Males | |
|---|---|---|---|
| PSS ≥ 14 | 368 (76.2) | 233 (72.8) | 0.28 |
| PHQ9 ≥ 10 | 144 (30.5) | 72 (23.1) | 0.023 |
| Known depression | 31 (6.4) | 7 (2.2) | 0.006 |
| GAD7 ≥ 10 | 94 (20.3) | 61 (19.8) | 0.854 |
| Known anxiety | 99 (20.5) | 44 (13.8) | 0.014 |
1 Abbreviations: PSS, Perceived Stress Scale; PHQ9, Patient Health Question 9; GAD7, Generalized Anxiety Disorder 7.